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Summary Survival analysis of 144 histologically confirmed cases of colon carcinoma diagnosed in a 12 year
period (1971-82) at the Tampere University Hospital was performed to test the hypothesis that p53
overexpression is associated with a poor clinical outcome. Immunohistochemical staining ofparaffin-embedded
sections using a polyclonal antibody CM-1 against p53 protein was performed to identify aberrant expression
of the p53 tumour-suppressor gene. Si'xty-nine per cent of the tumours (100/144) showed overexpression of the
p53 protein. The prevalence of p53 overexpression was independent of age and sex of the patient and subsite
of the tumour, but was slightly, although not statistically significantly, higher in advanced than in localised
tumours. Overexpression was associated with a higher S-phase fraction. Some indication of a larger proportion
of aneuploid tumours among those with overexpression was also observed, although this finding did not reach
statistical significance. Significantly reduced patient survival for tumours with p53 overexpression was found.
Patients with p53-overexpressing tumours had a corrected 5 year survival rate of 37% compared with 58%
among patients whose tumours had normal expression of p53. The corresponding 10 year rates were 34% and
54%. In the multivariate analysis using a Cox model, the survival difference was independent of age and sex of
the patient, as well as of subsite and stage of the tumour. Furthermore, the effect of p53 overexpression
remained after controlling for flow cytometric parameters in an analysis of a subset of tumours. Thus, p53
overexpression appears to be a useful prognostic indicator in colon carcinoma.
Mutations in the p53 gene have been detected in diverse
human cancers (Nigro et al., 1989; Hollstein et al., 1991).
They have been the subject of intense research during recent
years. The gene has been localised to the short arm of human
chromosome 17 (Hollstein et al., 1991; Levine et al., 1991).
In normal cells, the p53 protein regulates transcription of
several genes and, thus, cell proliferation and differentiation.
It has been shown to arrest the cell cycle at GI phase (Kastan
et al., 1991; Lin et al., 1992) and induce apoptosis (Shaw et
al., 1992) in response to DNA damage. A gene that is
probably an important mediator of its effects has recently
been identified (El-Deiry et al., 1993).
The levels of p53 protein in normal cells and tissues are
extremely low because of the protein's short half-life, and are
undetectable by standard immunohistochemical staining
(Rodriguez et al., 1990). Most forms of mutations result in
the formation of an abnormal protein with novel oncogenic
properties and prolonged half-life (Finlay et al., 1988). The
accumulation of such mutated protein in the tumour cell
nuclei can be detected by immunohistochemical staining
(Scott et al., 1991). This does not apply to frameshift and
chain-terminating (nonsense) mutations, which do not result
in elevated p53 protein content. However, these constitute
less than 20% of all mutations in human cancers (Hollstein
et al., 1991).
Some indication of the prognostic significance of the muta-
tions or resulting protein overexpression has been reported in
colon carcinoma (Kern et al., 1989; Remvikos et al., 1992;
Starzynska et al., 1992; Sun et al., 1992) and other cancers
(Ostrowski et al., 1991; Isola et al., 1992; Martin et al., 1992;
Quinlan et al., 1992; Thor et al., 1992; Visakorpi et al.,
1992).
In this study, we analysed the effect of immunohisto-
chemically detectable p53 overexpression on the long-term
survival in an unselected series of colon carcinoma
patients.
Material and methods
All cases of histologically confirmed carcinoma of the colon
that were diagnosed at Tampere University Hospital between
1971 and 1982 (n = 258) were identified from the nationwide,
population-based Finnish Cancer Registry (Saxesn & Teppo,
1978). Also, information on subsite of the tumour and stage
of disease at diagnosis was obtained from the Cancer Regis-
try.
Of the 258 tumours originally identified, 114 cases were
excluded on the basis of either missing or unusable tissue
blocks. The remaining 144 cancer cases constituted the series
used in the survival analyses.
Paraffin blocks were derived from the archives of the
Tampere University Hospital, Department of Pathology. The
original diagnostic slides were reviewed by one of us (J.I.) for
diagnostic confirmation and for selection of representative
tissue blocks for immunohistochemical and flow cytometnrc
analyses. One histologically representative tissue block was
chosen for each case.
Sections (3-5 pm) from routinely fixed (for at least 24 h in
neutral, buffered formalin), paraffin-embedded blocks were
mounted on adhesive-treated slides (Vectabond; Vector
Laboratories, Burlingame, CA, USA). The slides were
dewaxed, rehydrated and stained using a standard avidin-
biotin-enhanced technique (Vectastain Elite Kit; Vector
Laboratories). CM-1, a rabbit polyclonal antiserum to the
p53 protein, was used (Novocastra Laboratories, Newcastle,
UK) at a dilution of 1:1,200 and incubated overnight at
+ 4°C. The CM-1 antibody is specific for both the wild-type
and mutant forms of the p53 protein (Midgley et al., 1992).
Diaminobenzidine (0.5 M in phosphate-buffered saline with
0.03% hydrogen peroxide) was used as chromogen.
Stained slides were scored by evaluating the percentage of
p53-immunopositive cancer cell nuclei. At least 500 cells per
tumour were evaluated with a 25 x magnification from the
fields with the most positive cells (as assessed with a smaller
magnification). Only those with strong () 20%) positive
staining were classified as overexpressing the p53 gene
(Figure 1); all others were classified as having normal p53
expression. No immunostaining was seen in non-malignant
cells.
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All slides were evaluated in a blinded fashion, i.e. without
knowledge of the clinical outcome of the patients.
The immunohistochemical assay for p53 protein overex-
pression in paraffin-embedded tissues has been validated in
our previous studies (Isola et al., 1992; Visakorpi et al.,
1992). The T47D cell line, which is a breast cancer cell line
with a well-documented p53 mutation (Bartek et al., 1990),
was used as a positive control. The T47D cells were fixed
with buffered formalin for 24 h, dehydrated with acetone and
pelleted in fluid paraffin (60'C) in test tubes. These blocks
were mounted and stained similarly to the clinical samples.
The normal colonic tissue was used as a negative control.
DNA flow cytometry was performed on dewaxed, rehy-
drated and trypsin-treated 50lum sections of paraffin-
embedded tumours as previously descnbed (Kallioniemi et
al., 1991).
The patients were followed up for date of death until 31
December 1991 through the Finnish Population Registry by
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Fuge Immunohistochemical staining of p53 protein using the
polyclonal CM-i antibody. Strong nuclear staning can be seen in
the majority of carcinoma cells (haematoxcyhn counterstain,
bar= 100mn).
record linkage based on the unique personal identification
number issued for every Finnish citizen. The follow-up was
complete. Cause of death was available for the analyses and
corrected survival rates were used, i.e. only deaths caused by
colon cancer were taken as outcome events and all other
deaths as censored events. The EGRET statistical software
package was used for calculation of Kaplan-Meier estimates
of 5 and 10 year cumulative corrected survival rates and for
multivariate analyses using Cox proportional hazards method
(EGRET Users Manual, 1988).
Significance tests for heterogeneity were based on a Pear-
son's Xy test and those for survival rates on a likelihood ratio
test. All P-values are two-sided, and those less than 0.05 were
considered statistically significant.
Results
A high level of aberrant p53 expression () 20% of the
nuclei) was detected in 69% of the tumours (100 of 144). The
proportion of tumours with p53 overexpression was prac-
tically constant in both sexes and tumour subsites and in all
age groups (Table I). However, p53 overexpression was
slightly more common in advanced than in localised tumours
(78% vs 64%, P= 0.09).
When correlated with DNA flow cytometry analyses, p53
overexpression was associated with a higher mean S-phase
fraction (14.1% vs 11.3%, P= 0.05). A non-significantly
larger proportion of aneuploid tumours was observed among
tumours with p53 overexpression than among those with
normal p53 expression (39 of 86 positive vs 11 of 39 negative,
P = 0.07). No clear differences were observed in the mean
G2/M fraction (mean 4.4% in tumours with p53 expression vs
5.2% in tumours with normal p53 expression, P = 0.24).
A clear survival advantage was observed for patients with
tumours with normal p53 expression (10 year cumulative
corrected survival rate 54%, 95% CI 38-68%) as compared
with patients with p53-overexpressing tumours (34%, 95%
CI 25-43%) (Figure 2).
Table I Ten year cumulative corrected survival rate (CCSR) (with 95% confidence
interval) by p53 expression, sex, age, histological type, subsite and stage
p53 expression
Prognostic Normal Overexpression' Total
factor No. 10 year CCSR No. 10 year CCRS no.
Sex
Male 19 0.53 (0.26-0.74) 47 0.40 (0.26-0.53) 66
Female 25 0.56 (0.34-0.72) 53 0.29 (0.17-0.42) 78
Age (years)
0-49 6 0.67 (0.20-0.90) 7 0.29 (0.04-0.61) 13
50-64 18 0.67 (0.40-0.83) 40 0.42 (0.27-0.57) 58
65+ 20 0.38 (0.15-0.61) 53 0.28 (0.16-0.41) 73
Subsite
Proximal colonb 20 0.55 (0.31-0.74) 51 0.27 (0.15-0.39) 71
Distal colonc 22 0.58 (0.35-0.76) 48 0.40 (0.26-0.54) 73
DNA index
Diploid 28 0.49 (0.29-0.66) 47 0.32 (0.19-0.45) 75
Aneuploid 11 0.61 (0.27-0.84) 39 0.35 (0.21-0.50) 50
Unknown 5 0.80 (0.20-0.97) 14 0.38 (0.13-0.63) 19
S-phase fraction
0-9 14 0.50 (0.23-0.72) 19 0.25 (0.09-0.46) 33
10-14 10 0.53 (0.17-0.80) 20 0.40 (0.19-0.60) 30
15 + 6 0.33 (0.05-0.68) 24 0.38 (0.19-0.56) 30
Unknown 14 0.71 (0.39-0.88) 37 0.33 (0.19-0.49) 51
Stage
Local 25 0.68 (0.44-0.84) 45 0.47 (0.31-0.61) 70
Regional 9 0.33 (0.08-0.62) 13 0.46 (0.19-0.70) 22
Distant 5 0.20 (0.01-0.58) 36 0.11 (0.04-0.24) 41
Unknown 5 0.80 (0.20-0.97) 6 0.42 (0.06-0.77) 11
Total 44 0.54 (0.38-0.68) 100 0.34 (0.25-0.43) 144
'Defined as at least 20% staining-positive nuclei. b'ncluding caecum, ascending and
transverse colon. 'Including descending and sigmoid colon.p53 EXPRESSION AND COLON CANCER SURVIVAL 295
12 24 36 48 60 72 84 96 108 120
Months
Figwe 2 Cumulative corrected 10 year survival rate (CCSR)
among patients with normal and overexpression of p53 (defined
as at least 20% staining-positive nuclei).
In the stratified analysis, the prognostic significnc of p53
overexpression was evident among both males and females
(Table 1). The effect was observed in all age groups, but it
tended to diminish among older patients. The p53 over-
expression was associated with survival more closely among
patients with proximal than among those with distal
tumours. The survival advantage associated with normal p53
expression was clear in the subgroup of tumours with S-
phase fraction below 10%, but less pronounced in tumours
with a higher proliferative rate.
In stage-specific analyses, the absolute difference in the 10
year survival rate between tumours with p53 overexpression
and normal p53 expression was larger among patients with
lalised (47% vs 68%) than with non-localised tumours
(20% vs 29%) (Table I).
When age and subsite were controLld for simultaneously,
the prognostic effect of p53 overexpression remained
significant (Table II). After additional adjustment for stage,
the effect of p53 overexpression was reduced by approxi-
mately half. Adjustment for sex was not used because there
were no sex differences in the relative risk of death.
In the subset of tumours (n = 93) with information
available on both p53 expression and DNA flow cytometry,
adjustment for DNA index and S-phase fraction did not
reduce the prognostic signifi of p53 overexpression
(Table Ill).
Until recently, stage of disea&e at diagnosis and grade of
differentiation have been the only prognostic indicators of
clinical importance in colon cancer. In recent years, numer-
ous studies have been published describing the occurrence of
p53 mutations in colon cancer (Baker et al., 1989; Nigro et
al., 1989; van den Berg et al., 1989; Kawasaki et al.,
1992).
In 1992, the first report on the effect of the p53 mutations
on colon cancer survival was published (Sun et al., 1992),
and other reports soon followed (Remvikos et al., 1992;
Starzynska et al., 1992). In all the published studies, p53
mutation or overexpression was associated with poor prog-
nosis. However, the Swedish report published by Sun et al.
(1992) was the only one in which a reasonable number of
patients (>50) were followed up for at least 5 years and
multivariate analysis of survival was used. We were able to
demonstrate survival differences in cause of death-specific 10
year survival rates, i.e. to make extensive use of the inform-
ation on cause of death stated in the death certificates.
Furthermore, our study is the first one to assess p53 over-
expression in association with flow cytometry in a multi-
variate survival analysis.
The method of p53 protein staining employed in all studies
is quite similar, although different antibodies have been used.
However, Sun et al. (1992) found a prognostic effect for
cytoplasmic p53 protein, but not for nuclear p53 protein. In
Table I Relative risk of colon cancr death (with 95% confidence
interval) by p53 expresson, age, subsite and stage
p53 expresson
Adjusted for Normao Overexpressmonb Signfcaince
Crude 1 1.91 (1.15-3.20) 0.009
Age 1 1.85 (1.10-3.10) 0.020
Age, subsite 1 1.86 (1.11-3.11) 0.013
Age, subsite, stage 1 1.38 (0.81-2.36) 0.228
aReference category. bDefilned as at least 20% staining-positive
nuclei. Age, 0-49, 50-64 and 65 + years; subsite, proximal and
distal colon, stage, local, regional, distant and unknown.
Tab M H Relative risk of death due to colon cancer (with 95%
confidence interval) by p53 epssion and DNA flow cytometric
parmeters (using the dataset with complete DNA flow cytometry
and p53 staining iformation only, n = 93)
p53 expression
Adjustedfor Normat Overexpressione Signficance
Crude 1 1.53 (0.85-2.77) 0.147
DNA 1 1.59 (0.87-2.91) 0.125
SPF 1 1.52 (0.83-2.79) 0.165
DNA, SPF 1 1.56 (0.84-2.87) 0.145
'Reference category. b[)efined as at least 20'/! stain tive
nuclei. DNA (DNA index), diploid, aneuploid; SPF (S-phase
fraction), 0-9, 10-14, 15+%.
our analyses, the cytoplasmic p53 s g with the CM-I
antibody was very weak or absent, and did not exceed the
level of background staining. The same finding was observed
using a new monoclonal antibody D07 (J. Isola, unpublished
data).
Overexpression of the p53 gene, assessed by nuclear stain-
ing ofits protein product, was an indicator ofpoor long-term
survival in our study, especialy in localised tumours. The
prognostic signifi of p53 overexpression was indepen-
dent of age and sex of the patient, but more evident among
patients with tumours of the proximal than distal colon.
In our study, the S-phase fraction of tumours overexpress-
ing p53 was significntly higher than that oftumours without
accumulation of p53 protein. This suggests that the effect of
p53 overexpression leads to acceleration of cell proliferation.
However, adjustment for DNA flow cytometrc findings did
not diminish the prognostic significnce of p53 overexpres-
sion, which suggests that changes in the cell cycle are not the
only mechanism contributing to high malignant potential
associated with the p53 overexpression.
According to our results, p53 overexpression does not have
a clear prognostic effect among tumours with high pro-
liferative activity. It is possible that the tumours with normal
p53 protein content, but an elevated S-phase fraction, have
undergone mutation of some other oncogene or tumour-
suppressor gene, which could explain the poor prognosis of
patients with such tumours. The identification of other
mechanisms contributing to the metastatic potential of col-
onic carcinomas would be of interest, since the survival of
patients with metastatic colon cancer in our study was poor
irresptive of p53 expression.
Our results suggest that stage of disease is still the
strongest prognostic factor available (even though only TNM
staging was used) and that p53 overexpression can be used as
an additional prognostic indicator. However, by combining
the two factors more accurate prediction of disease outcome
is feasible, e.g. the 10 year survival rate among all patients
with localised disease was 54%, but the could be divided into
two distinct groups on the basis of p53 overexpression (with
survival rates of 68% vs 47%).
The fact that the effect of p53 overexpression is most
marked in localised tumours suggests that p53 overexpression
may be useful for identification of patients at high risk of
recurrence and who may thus benefit from more radical296 A. AUVINEN et al.
treatment approach and intensive medical follow-up after the
primary treatment. Correspondingly, improved prognostic
prediction may benefit patients with a low nrsk of disease
progression by allowing avoidance of unnecessary colostomy
or adjuvant chemotherapy.
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